Dietary Supplementation with L-Arginine in Patients with Breast-Cancer (greater-than-4 cm) Receiving Multimodality Treatment

report of a feasability study

Julie Brittenden, Steven Darryll Heys, I Miller, T K Sarkar, A W Hutcheon, Gillian Needham, Fiona Jane Gilbert, M McKean, A K Ahsee, O Eremin

Research output: Contribution to journalArticle

Abstract

L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers >4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day(-1) for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36% and 'moderate' in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

Original languageEnglish
Pages (from-to)918-921
Number of pages4
JournalBritish Journal of Cancer
Volume69
Issue number5
Publication statusPublished - May 1994

Keywords

  • TOTAL PARENTERAL-NUTRITION
  • INDUCTION CHEMOTHERAPY
  • MANAGEMENT
  • RADIOTHERAPY
  • ADJUVANT
  • THERAPY
  • total parenteral-nutrition
  • induction chemotherapy
  • management
  • radiotherapy
  • adjuvant
  • therapy

Cite this

Dietary Supplementation with L-Arginine in Patients with Breast-Cancer (greater-than-4 cm) Receiving Multimodality Treatment : report of a feasability study. / Brittenden, Julie; Heys, Steven Darryll; Miller, I; Sarkar, T K ; Hutcheon, A W ; Needham, Gillian; Gilbert, Fiona Jane; McKean, M; Ahsee, A K ; Eremin, O .

In: British Journal of Cancer, Vol. 69, No. 5, 05.1994, p. 918-921.

Research output: Contribution to journalArticle

Brittenden, J, Heys, SD, Miller, I, Sarkar, TK, Hutcheon, AW, Needham, G, Gilbert, FJ, McKean, M, Ahsee, AK & Eremin, O 1994, 'Dietary Supplementation with L-Arginine in Patients with Breast-Cancer (greater-than-4 cm) Receiving Multimodality Treatment: report of a feasability study', British Journal of Cancer, vol. 69, no. 5, pp. 918-921.
Brittenden, Julie ; Heys, Steven Darryll ; Miller, I ; Sarkar, T K ; Hutcheon, A W ; Needham, Gillian ; Gilbert, Fiona Jane ; McKean, M ; Ahsee, A K ; Eremin, O . / Dietary Supplementation with L-Arginine in Patients with Breast-Cancer (greater-than-4 cm) Receiving Multimodality Treatment : report of a feasability study. In: British Journal of Cancer. 1994 ; Vol. 69, No. 5. pp. 918-921.
@article{057c3a65cdb2441d87dd0afa92a9ea42,
title = "Dietary Supplementation with L-Arginine in Patients with Breast-Cancer (greater-than-4 cm) Receiving Multimodality Treatment: report of a feasability study",
abstract = "L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers >4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day(-1) for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95{\%} of patients had a clinical response: complete response in 30{\%} and partial response in 65{\%}. Imaging, ultrasound and mammography revealed response rates of 91{\%} and 76{\%} respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18{\%} of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36{\%} and 'moderate' in 30{\%} of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.",
keywords = "TOTAL PARENTERAL-NUTRITION, INDUCTION CHEMOTHERAPY, MANAGEMENT, RADIOTHERAPY, ADJUVANT, THERAPY, total parenteral-nutrition, induction chemotherapy, management, radiotherapy, adjuvant, therapy",
author = "Julie Brittenden and Heys, {Steven Darryll} and I Miller and Sarkar, {T K} and Hutcheon, {A W} and Gillian Needham and Gilbert, {Fiona Jane} and M McKean and Ahsee, {A K} and O Eremin",
year = "1994",
month = "5",
language = "English",
volume = "69",
pages = "918--921",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Dietary Supplementation with L-Arginine in Patients with Breast-Cancer (greater-than-4 cm) Receiving Multimodality Treatment

T2 - report of a feasability study

AU - Brittenden, Julie

AU - Heys, Steven Darryll

AU - Miller, I

AU - Sarkar, T K

AU - Hutcheon, A W

AU - Needham, Gillian

AU - Gilbert, Fiona Jane

AU - McKean, M

AU - Ahsee, A K

AU - Eremin, O

PY - 1994/5

Y1 - 1994/5

N2 - L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers >4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day(-1) for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36% and 'moderate' in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

AB - L-Arginine has been shown, in human breast cancers, to increase protein synthesis and the number of cells in the growth phase of the cell cycle. L-Arginine, therefore, may potentiate the response of breast cancers to cell cycle-specific cytotoxic agents. This phase II pilot study assessed the clinical, radiological and pathological responses in 44 patients with breast cancers >4 cm in diameter (46 tumours: T2, n = 6; T3, n = 22; T4, n = 19), who received oral L-arginine 30 g day(-1) for 3 days prior to each cycle of CHOP chemotherapy, followed after 4-6 cycles by radiotherapy. Following this treatment, 95% of patients had a clinical response: complete response in 30% and partial response in 65%. Imaging, ultrasound and mammography revealed response rates of 91% and 76% respectively. Surgery was performed in 43 patients. Histological examination revealed that in 18% of cases there was no residual evidence of tumour. Furthermore, if residual tumour was identified, the degree of destruction was graded as 'severe' in 36% and 'moderate' in 30% of cases. Further studies are now required to evaluate the potential beneficial use of nutritional pharmacology in combination with existing treatment regimens.

KW - TOTAL PARENTERAL-NUTRITION

KW - INDUCTION CHEMOTHERAPY

KW - MANAGEMENT

KW - RADIOTHERAPY

KW - ADJUVANT

KW - THERAPY

KW - total parenteral-nutrition

KW - induction chemotherapy

KW - management

KW - radiotherapy

KW - adjuvant

KW - therapy

M3 - Article

VL - 69

SP - 918

EP - 921

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -